Search results
Showing 1276 to 1290 of 1335 results for primary care
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued [GID-TA10228]
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued [GID-TA10330]
Discontinued [GID-TA10811]
Discontinued [GID-TA10133]
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Discontinued [GID-TA11000]